Coeptis Therapeutics, and Bull Horn Holdings today announced a definitive merger agreement for a business combination.
Under the terms of the agreement, a wholly-owned subsidiary of Bull Horn will merge with Coeptis and the holders of the outstanding Coeptis shares will receive equity in Bull Horn valued at $175 million (subject to adjustments, including redemptions).
Pending shareholder approval, the deal is anticipated to close in the third quarter.
Coeptis is a biopharmaceutical company developing cell therapy platforms for cancer. The company was founded in 2017 and is headquartered in Wexford, Pa.
Bull Horn raised $75 million in a November 2020 IPO. At that time the SPAC said it intended to focus on leading sports, entertainment and brand companies that have potential for brand and commercial growth. Read more.
